ASH Meeting on Lymphoma Biology

ASH Meeting on Lymphoma Biology

Highlights and interviews from the American Society of Hematology’s Meeting on Lymphoma Biology

ASH Meeting on Lymphoma Biology: Mechanisms of Ibrutinib Resistance Varied in ABC DLBCL

Tuesday, November 22nd, 2016
Lymphoma cells may develop resistance to the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib using a variety of potentially druggable pathways, opening the door to...

ASH Meeting on Lymphoma Biology: Early Data Show EZH2 Inhibitor Active in Non-Hodgkin Lymphoma

Tuesday, July 5th, 2016
The EZH2 inhibitor EPZ-6438 appears to be a well-tolerated drug and is showing early evidence of anti-lymphoma activity in patients with non-Hodgkin lymphoma of...

ASH Meeting on Lymphoma Biology: Creating a Roadmap for Future Research

Monday, April 18th, 2016
More than 350 lymphoma experts from around the world convened at the American Society of Hematology’s first Meeting on Lymphoma Biology to share cutting-edge...

Harnessing the Power of Gene Editing

Monday, March 21st, 2016
For years, scientists have been manipulating genes in animal and human cells to gain a better understanding of how genomes work, with an eye...

ASH Meeting on Lymphoma Biology: Potent Small-Molecule BCL6 Inhibitor Active against ABC-, GCB-DLBCL Cells

Tuesday, January 12th, 2016
Researchers have identified a novel, potent, and specific BCL6 inhibitor that effectively inhibited tumor growth in vitro and in vivo in activated B-cell (ABC)...

Ibrutinib Shows Survival Benefit in Previously Treated CLL/SLL Patients with High-Risk Disease

Tuesday, December 15th, 2015
Longer-term data from the phase III RESONATE trial – a head-to-head comparison of ibrutinib and ofatumumab – continue to demonstrate ibrutinib’s efficacy in patients...

Tazemetostat for Patients with Pretreated Non-Hodgkin Lymphoma

Monday, June 29th, 2015
Preliminary data from an ongoing, global, phase II trial of tazemetostat, a first-in-class EZH2 inhibitor, in patients with relapsed or refractory non-Hodgkin lymphoma (NHL)...

R-EPOCH May Be Viable Option for Patients with High-Risk DLBCL

Sunday, May 24th, 2015
Results from a single-center study show that the drug combination R-EPOCH leads to a high overall response rate (ORR) in patients with high-risk diffuse...
Advertisement

Current Issue

March 2017, Volume 3, Issue 4

This issue takes a look at diversity in the medical education system, provides a hematology drug pipeline update, and more.